TG Therapeutics initiated with a Buy at MLV & Co; tgt $9; killing cancer better (3.97)
MLV
& Co initiates TGTX with a Buy and price target of $9. TGTX is an
early/mid-stage oncology-focused biotech with two
potential-best-in-class candidates, TG-1101 (in P2) and TGR-1202 (in
P1), that target B-cell lymphomas. MLV projects ~$10B in combined 2033
WW sales, in a current $7B market that it thinks could grow several-fold
over the next decades with the advent of new agents and the embrace of
combination approaches.
--------------------------------------------------------------------------------------------------------------------
I didn't buy tgtx when the jman posted about it back in 2013 but I watched and waited and about a week ago pulled the trigger.
This approval for tgtx is a very nice one for LGND as it's a 6 to 9 percent royalty drug.
So I'm hoping the jman was corrent in tgtx getting to 10b in sales over the next 10 years or so as I'm sure a large part of that would be the newly approved drug.
BTW, tvtx also announced significant results a couple of days ago with plans to file for approval based on those results. And that is even a better royalty rate.
Things are definitely looking up for lgnd and it's happening a lot sooner than I thought. Sometime it's good to be wrong.
Thanks jman for putting tgtx on my watch list 8 years ago.
